FoundationOne®CDx (F1CDx) and FoundationOne® Liquid CDx
FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic method for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes, select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB). The testing is performed using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling for patients with solid malignant neoplasms. Product claims are as follow:
For Non-Small Cell Lung Cancer (NSCLC), these mutations are relevant and related to therapy selection
- EGFR exon 19 deletions & EGFR exon 21 L858R alterations
- EGFR exon 20 T790M alterations
- ALK rearrangements
- BRAF V600E
FDA approved therapy selection based on mutation detection
- Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib), or Tarceva® (erlotinib)
- Tagrisso® (osimertinib)
- Alecensa® (alectinib), Xalkori® (crizotinib) or Zykadia® (ceritinib)
- Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)
For Melanoma, these mutations are relevant and related to therapy selection
- BRAF V600E
- BRAF V600E or V600K
FDA approved therapy
- Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib)
- Mekinist® (trametinib) or Cotellic® (cobimetinib), in combination with Zelboraf® (vemurafenib)
For Breast Cancer, these mutations are relevant and related to therapy selection
- ERBB2 (HER2) amplification
- PIK3CA alterations
FDA approved therapy
- Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab)
- Piqray® (alpelisib)
For Colorectal Cancer, these mutations are relevant and related to therapy selection
- KRAS wild-type (absence of mutations in codons 12 and 13)
- KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)FDA approved thereapy
- Erbitux® (cetuximab)
- Vectibix® (panitumumab)
For Ovarian Cancer, these mutations are relevant and related to therapy selection
- RAS wild-type (absence of mutations in codons 12 and 13)
- KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)
FDA approved therapy
- Erbitux® (cetuximab)
- Vectibix® (panitumumab)
- Companion diagnostic test in non-small cell lung cancer with EGFR, ALK, BRAF mutations for treatment with Gilotrif®, Iressa®, Tagrisso®, or Tarceva®
- Companion diagnostic test in melanoma with BRAF mutation and for treatment with Tafinlar® or Zelboraf®
- Companion diagnostic test in Breast cancer with ERBB2 (HER2) amplification and for treatment with Herceptin®, Kadcyla® or Perjeta®
- Companion diagnostic test for colorectal cancer with KRAS wild-type (absence of mutations in codons 12 and 13) in treatment with Erbitux® (cetuximab)
- Companion diagnostic test for Ovarian cancer with BRCA1/2 alterations for treatment with Lynparza® (olaparib) or Rubraca® (rucaparib)
- In cancers stage III metastatic, recurrent, relapsed, or refractory cancers, in addition to the Stage IV relapsed or refractory cancers when searching better therapy as well as cancers that previous testing did not elucidate treatment solution and disease management
No reportable variants were identified (Negative for mutation analyzed)
Formalin-fixed paraffin embedded (FFPE) tumor tissue specimens, whole blood for liquid biopsy.
- Lung Cancer. 2014 Mar;83(3):329-33. [PMID: 24439568]
- J Clin Pathol. 2013 May;66(5):381-5. [PMID: 23386666]
- Diagn Mol Pathol 22, 138-43 (2013). [PMID: 23846439]
- Clin Oncol 34:3518-3528, 2016. [PMID: 27573653]
- J Clin Oncol. 2009 Jun 20;27(18):2962-9. [PMID: 19364966]
- Cancer Discov. 2018 Mar;8(3):OF4. doi: 10.1158/2159-8290.CD-NB2017-182. [PMID: 29339360]